<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Human African trypanosomiasis: Treatment and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Human African trypanosomiasis: Treatment and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Human African trypanosomiasis: Treatment and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjeev Krishna, MA, BMChB, DPhil, FRCP, ScD, FMedSci
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andreas Lindner, MD, MSc, DTMH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Veerle Lejon, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites [
         <a href="#rid1">
          1-3
         </a>
         ]. There are two forms of the disease: an acute form occurring mainly in East and Southern Africa and caused by
         <em>
          Trypanosoma brucei rhodesiense
         </em>
         (rhodesiense HAT) and a more chronic form occurring mainly in West and Central Africa caused by
         <em>
          Trypanosoma brucei gambiense
         </em>
         (gambiense HAT)  (
         <a class="graphic graphic_table graphicRef85846" href="/z/d/graphic/85846.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. These two-parasite subspecies have identical morphologic appearances, and both are transmitted by tsetse flies (
         <em>
          Glossina
         </em>
         ). However, the two forms of HAT differ with respect to epidemiology, clinical presentation, and management.
        </p>
        <p>
         The treatment and prevention of African trypanosomiasis will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of these infections are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3774109872">
         <span class="h1">
          TREATMENT OF GAMBIENSE HAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In endemic areas, management is guided by regional or national protocols which may include specific diagnostic criteria [
         <a href="#rid1">
          1
         </a>
         ]. In general, management considerations for gambiense HAT include patient age and weight, drug availability, clinical manifestations, and cerebrospinal fluid (CSF) findings; the approach is summarized below and in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130497" href="/z/d/graphic/130497.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1418135285">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment selection is based on assessment for signs and symptoms of severe disease  (
         <a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">
          table 2
         </a>
         ). CSF examination is required for patients with signs and symptoms of severe disease as well as for patients who cannot be treated with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         .
        </p>
        <p class="headingAnchor" id="H1662884797">
         <span class="h3">
          Patients &lt;6 years or &lt;20 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients &lt;6 years old or &lt;20 kg body weight warrant routine lumbar puncture.
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          Fexinidazole
         </a>
         is not approved for this group  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If CSF demonstrates white blood cell (WBC) ≤5 cells/microL and no trypanosomes, treatment consists of
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         (4 mg/kg/day intramuscular or intravenous [over 2 hours] for 7 days). Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Pentamidine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If CSF demonstrates WBC &gt;5 cells/microL and/or presence of trypanosomes, or if lumbar puncture is not feasible, treatment consists of nifurtimox-eflornithine combination therapy (NECT;
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          nifurtimox
         </a>
         15 mg/kg orally in three doses for 10 days and eflornithine 400 mg/kg per day intravenously in two 2-hour infusions for 7 days). Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Nifurtimox-eflornithine combination therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H300049625">
         <span class="h3">
          Patients ≥6 years and ≥20 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among individuals ≥6 years and ≥20 kg in endemic areas with no suspicion for severe second-stage disease  (
         <a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">
          table 2
         </a>
         ), lumbar puncture is not required; the preferred treatment consists of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (weight-based dosing once daily for 10 days)  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ). Outside of resource-limited settings, CSF examination is preferred for treatment selection.
        </p>
        <p>
         For patients with suspicion for severe second-stage disease  (
         <a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">
          table 2
         </a>
         ), routine lumbar puncture is warranted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If CSF demonstrates WBC &lt;100 cells/microL, treatment consists of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (weight-based dosing once daily for 10 days)  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ), given similar treatment success rates (relative to NECT) with less toxicity. (See
         <a class="local">
          'Fexinidazole'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         should be pursued only if there is high confidence in appropriate follow-up for early detection of relapse. Fexinidazole should be administered under direct observation of trained health personnel on an inpatient or outpatient basis [
         <a href="#rid1">
          1
         </a>
         ]. Patients with history of psychiatric disorders should be hospitalized during treatment to observe for adverse neuropsychiatric reactions. Criteria for outpatient treatment include reliable food intake, anticipated adherence, absence of psychiatric disorders, and body weight ≥35 kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Fexinidazole'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If CSF demonstrates WBC ≥100 cells/microL, or if lumbar puncture is not feasible, treatment consists of NECT: combination therapy with
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          nifurtimox
         </a>
         (15 mg/kg orally in 3 doses for 10 days) and eflornithine (400 mg/kg per day intravenously in 2 infusions [over 2 hours each] for 7 days)  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ), given greater treatment success rates compared with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         . Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Nifurtimox-eflornithine combination therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H598692333">
         <span class="h2">
          Alternative and rescue treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preferred treatment approach is summarized above and in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130497" href="/z/d/graphic/130497.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Patients &lt;6 years or &lt;20 kg'
         </a>
         above and
         <a class="local">
          'Patients ≥6 years and ≥20 kg'
         </a>
         above.)
        </p>
        <p>
         For circumstances in which preferred treatment is not available, is not tolerated, or is not effective, alternative and rescue therapies are summarized in the table  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         In general, if
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         cannot be given, CSF examination should be used to guide subsequent management; options include
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         or NECT (see
         <a class="local">
          'Efficacy, administration, and adverse effects'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient relapses after initial treatment with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         or NECT (depending on age/weight and CSF WBC count) should be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient relapses after initial treatment with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         , NECT should be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient relapses after treatment with NECT, alternative approaches include NECT-long (in which eflornithine is administered for 14 days rather than for 7 days) or eflornithine monotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         is a regarded as an agent of last resort due to toxicity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1588182555">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on safety of antitrypanosomal drugs in pregnancy are very limited. The World Health Organization guidelines favor management based on clinical assessment including disease severity and pregnancy stage [
         <a href="#rid1">
          1
         </a>
         ]. Treatment during pregnancy may reduce the likelihood of vertical transmission;
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         and
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         may be given after the first trimester. In general,
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          nifurtimox
         </a>
         , eflornithine alone or NECT should be avoided during pregnancy; however, in the setting of moderate to severe disease, administration of these agents with the goal of life-saving treatment is appropriate. The benefits and risks must be clearly explained to the patient.(See
         <a class="local">
          'Efficacy, administration, and adverse effects'
         </a>
         below.)
        </p>
        <p>
         Newborns should be examined clinically, undergo blood concentration methods to evaluate for presence of circulating trypanosomes, and should be followed clinically [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Information on the use of antitrypanosomal drugs in breastfeeding women is very limited. Breastfeeding may continue during HAT treatment.
        </p>
        <p class="headingAnchor" id="H450673196">
         <span class="h1">
          TREATMENT OF RHODESIENSE HAT
         </span>
        </p>
        <p class="headingAnchor" id="H1369340784">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of rhodesiense HAT is guided by lumbar puncture findings. First- (hemolymphatic) stage disease consists of ≤5 white blood cells (WBC)/microL and no trypanosomes in the cerebrospinal fluid (CSF); second- (meningoencephalitic) stage disease consists of &gt;5 WBC/microL and/or presence of trypanosomes in CSF. In December 2023, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive scientific opinion of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         as treatment of first and second stage rhodesiense HAT in adults and children ≥6 years old and weighing ≥20 kg [
         <a href="#rid6">
          6
         </a>
         ]. As use of fexinidazole for management of first and second stage rhodesiense HAT supplants other drugs, lumbar puncture may no longer be needed. Updated recommendations from the WHO are in progress. (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Cerebrospinal fluid'
         </a>
         .)
        </p>
        <p>
         Given that trypanosomes are commonly detected on blood smear in the setting of rhodesiense HAT, the first test dose of
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         (4 to 5 mg/kg intravenously [IV] on day 1) is often administered prior to lumbar puncture, to reduce parasitemia and minimize the theoretic risk of iatrogenic introduction of trypanosomes into the CSF (in case of a traumatic lumbar puncture) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1158269822">
         <span class="h3">
          First-stage disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-line treatment of first stage rhodesiense HAT consists of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         for patients who are ≥6 years old and weigh ≥20 kg [
         <a href="#rid6">
          6
         </a>
         ]. In vitro and in vivo studies have demonstrated that fexinidazole has activity against
         <em>
          T.b. rhodesiense
         </em>
         [
         <a href="#rid8">
          8
         </a>
         ]. The efficacy of fexinidazole in rhodesiense HAT has been assessed in a phase II/III clinical trial in Malawi and in Uganda [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         For patients &lt;6 years of age and/or weighing &lt;20kg or those who cannot receive
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         should be administered instead [
         <a href="#rid10">
          10
         </a>
         ]. The most commonly used suramin regimen consists of 4 to 5 mg/kg IV on day 1 (test dose, administered cautiously), followed by 5 injections of 20 mg/kg (max 1 g) IV weekly (eg, on days 3, 10, 17, 24, and 31) [
         <a href="#rid7">
          7
         </a>
         ]. Administration of a suramin test dose is important given the risk of immediate hypersensitivity reaction (1:20,000). Suramin should be administered by slow IV infusion. In addition, a urinalysis should be performed to check for proteinuria prior to each dose, given the potential for nephrotoxicity. (See
         <a class="local">
          'Suramin'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         may have efficacy against first-stage rhodesiense HAT, based on case reports of travelers and pharmacologic data [
         <a href="#rid7">
          7,11-13
         </a>
         ]. In regions where pentamidine is more accessible than
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         , pentamidine may be used as initial therapy (especially in the setting of acute illness) until suramin therapy can be obtained and administered. (See
         <a class="local">
          'Pentamidine'
         </a>
         below.)
        </p>
        <p>
         In the setting of treatment failure,
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         (dosing as for second-stage disease) may be given as a rescue therapy. (See
         <a class="local">
          'Second-stage disease'
         </a>
         below.)
        </p>
        <p>
         Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Fexinidazole'
         </a>
         below and
         <a class="local">
          'Suramin'
         </a>
         below and
         <a class="local">
          'Pentamidine'
         </a>
         below and
         <a class="local">
          'Melarsoprol'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3692632594">
         <span class="h3">
          Second-stage disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for second-stage disease consists of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         . New WHO recommendations are expected to be published soon.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line treatment
         </strong>
         – First-line treatment of second stage rhodesiense HAT consists of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (weight-based dosing once daily for 10 days) for individuals ≥6 years of age and weighing ≥20 kg [
         <a href="#rid6">
          6
         </a>
         ]. Fexinidazole should be administered under direct observation of trained health personnel on an inpatient or outpatient basis [
         <a href="#rid1">
          1
         </a>
         ]. Patients with history of psychiatric disorders should be hospitalized during treatment to observe for adverse neuropsychiatric reactions. Criteria for outpatient treatment include reliable food intake, anticipated adherence, absence of psychiatric disorders, and body weight ≥35 kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Fexinidazole'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In vitro and in vivo studies have demonstrated that
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         has activity against
         <em>
          T. b.
         </em>
         <em>
          rhodesiense
         </em>
         [
         <a href="#rid14">
          14
         </a>
         ]. A study on the efficacy and safety of fexinidazole in patients with rhodesiense HAT was completed in October 2022; data has not been published [
         <a href="#rid15">
          15
         </a>
         ]. European Medicines Agency (EMA) approved fexinidazole for the treatment of rhodesiense HAT in December 2023 [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative treatment
         </strong>
         – For patients &lt;6 years of age and/or weighing &lt;20kg or those who cannot receive
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         , an arsenical compound associated with high frequency of severe, life-threatening adverse effects, can be administered instead [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         dosing consists of 2.2 mg/kg/day (maximum 180 mg/day) IV for 10 days. Alternative dosing schedules have not been proven to have significant advantages [
         <a href="#rid6">
          6
         </a>
         ]. Details regarding drug efficacy, logistics of administration, and adverse effects are discussed below. (See
         <a class="local">
          'Melarsoprol'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         should be coadministered with oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         1 mg/kg per day (maximum dose 50 mg) for 9 days, followed by a 3-day taper (day 10: 0.75 mg/kg; day 11: 0.5 mg/kg; day 12: 0.25 mg/kg) [
         <a href="#rid1">
          1
         </a>
         ]. Use of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         reduces the likelihood of developing melarsoprol-induced encephalopathy [
         <a href="#rid16">
          16,17
         </a>
         ] (see
         <a class="local">
          'Melarsoprol'
         </a>
         below).
        </p>
        <p>
        </p>
        <p>
         Onset of encephalopathy should prompt
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         discontinuation.
        </p>
        <p>
         For patients with relapse after treatment with
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         , a repeat course of melarsoprol may be given.
        </p>
        <p class="bulletIndent1">
         Use of
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         for treatment of rhodesiense HAT is supported by a proof-of-concept trial and utilization study using historical controls as comparator [
         <a href="#rid16">
          16
         </a>
         ]. Among 107 patients in Tanzania and Uganda treated with melarsoprol (10-day regimen), the case fatality rate during treatment was 8.4 percent (versus 9.3 percent in historic controls treated with other regimens). Among discharged patients, 96 percent were clinically cured at 12-month follow-up.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H328332646">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on treatment of rhodesiense HAT in pregnant or lactating women are very limited [
         <a href="#rid18">
          18
         </a>
         ]. Given the acute and rapidly progressive clinical presentation, treatment usually cannot be delayed until after delivery [
         <a href="#rid1">
          1
         </a>
         ]. Newborns should be examined clinically, checked for the presence of circulating trypanosomes in the blood and CSF, and should be followed clinically [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2703578872">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         If treatment is uncomplicated, no routine follow-up is needed in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with gambiense HAT treated with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         , nifurtimox-eflornithine combination therapy, or eflornithine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with rhodesiense HAT treated with
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         or
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
        </p>
        <p>
        </p>
        <p>
         These regimens have high efficacy and completion of treatment can be documented given the need for intravenous or intramuscular administration. Such patients should be advised to return for evaluation if symptoms recur [
         <a href="#rid1">
          1,7
         </a>
         ].
        </p>
        <p>
         For patients treated with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         , issues related to follow-up are discussed above. (See
         <a class="local">
          'Patients ≥6 years and ≥20 kg'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1277217014">
         <span class="h1">
          APPROACH TO RELAPSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with signs or symptoms suggestive of relapse, blood examination and lumbar puncture should be performed. For patients with gambiense HAT, the preferred tool for blood examination is mini anion-exchange centrifugation technique (mAECT); for rhodesiense HAT, blood smear may be performed followed by mAECT if smear is negative. (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnostic tools'
         </a>
         .)
        </p>
        <p>
         A definitive diagnosis of relapse is established if trypanosomes are observed in any body fluid or tissue.
        </p>
        <p>
         If trypanosomes are not observed, the cerebrospinal fluid (CSF) white blood cell (WBC) count may be used to establish a presumptive diagnosis of relapse according to the following criteria [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Up to four months after treatment – Up to four months after completion of treatment, the CSF WBC count is not reliable [
         <a href="#rid7">
          7,19
         </a>
         ]; diagnosis of relapse may be based only on observation of trypanosomes. If no trypanosomes are observed, the decision to administer rescue treatment should be based on clinical manifestations. If rescue treatment is not pursued, follow-up assessment with lumbar puncture at six months is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At five to nine months after treatment:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After treatment with nifurtimox-eflornithine combination therapy (NECT), eflornithine, or
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         (for second-stage HAT), or after treatment with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (for first-stage HAT or nonsevere second-stage HAT) [
         <a href="#rid1">
          1,7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC ≥50 cells/microL: Presumptive diagnosis of relapse; administer rescue treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC 6 to 49 cells/microL: The evolution of the WBC count is uncertain; follow-up assessment at 12 months is warranted. The decision to administer rescue treatment should be based on clinical features suggesting relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC ≤5 WBC: Relapse unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After treatment with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         or
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         (for first-stage HAT) [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC &gt;20 cells/microL: Presumptive diagnosis of relapse; administer rescue treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC 6 to 20 cells/microL: The evolution of the WBC count is uncertain; follow-up assessment at 12 months is warranted. The decision to administer rescue treatment should be based on clinical features suggesting relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC ≤5 WBC: Relapse unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At 10 to 24 months after treatment [
         <a href="#rid1">
          1,7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After treatment with NECT, eflornithine, or
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         (for second-stage HAT), or after treatment with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (for first-stage HAT or nonsevere second-stage HAT) [
         <a href="#rid1">
          1,7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC &gt;20 cells/microL: Presumptive diagnosis of relapse; administer rescue treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC ≤20 WBC: Relapse unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After treatment with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         or
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         (for first-stage HAT) [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC &gt;20 cells/microL: Presumptive diagnosis of relapse; administer rescue treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC 6 to 20 cells/microL: The evolution of the WBC count is uncertain; further follow-up assessment is warranted. The decision to administer rescue treatment should be based on clinical features suggesting relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CSF WBC ≤5 WBC: Relapse unlikely.
        </p>
        <p>
        </p>
        <p>
         Use of the above thresholds for diagnosis of relapse is based on second-stage gambiense HAT patient follow-up data [
         <a href="#rid19">
          19-21
         </a>
         ]. In a prospective study including 360 patients with gambiense HAT in the Democratic Republic of Congo, the above criteria had high sensitivity and specificity (94 and 98 percent, respectively) for prediction of treatment outcome [
         <a href="#rid20">
          20
         </a>
         ]. Similarly, in a study including more than 2000 patients with second-stage gambiense HAT in six African countries, these criteria had high sensitivity and specificity (87 and 98 percent, respectively) for prediction of treatment outcome [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Data for follow-up evaluation of first-stage gambiense HAT and rhodesiense HAT are sparse [
         <a href="#rid19">
          19,22-24
         </a>
         ].
        </p>
        <p>
         Unreliable tools for detection of relapse include detection of trypanosomal DNA or antibodies in blood or CSF [
         <a href="#rid20">
          20,25,26
         </a>
         ]. Tools under investigation include detection of trypanosomal RNA [
         <a href="#rid27">
          27-29
         </a>
         ] and CSF neopterin levels [
         <a href="#rid30">
          30
         </a>
         ]. Neopterin is a marker for cellular immune activation and remains largely a research tool.
        </p>
        <p class="headingAnchor" id="H2017188550">
         <span class="h1">
          ANTITRYPANOSOMAL AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H609943881">
         <span class="h2">
          Efficacy, administration, and adverse effects
         </span>
        </p>
        <p class="headingAnchor" id="H2733488678">
         <span class="h3">
          Fexinidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          Fexinidazole
         </a>
         is recommended for the treatment of gambiense HAT in individuals ≥6 years of age and ≥20 kg in weight in whom there is no suspicion of severe second-stage disease, or in whom cerebrospinal fluid (CSF) analysis confirms white blood cell (WBC) &lt;100 cells/microL. Use of fexinidazole for treatment of second stage gambiense HAT should be limited to individuals with CSF WBC &lt;100 cells/microL. Further discussion of indications for fexinidazole are found above. (See
         <a class="local">
          'Patients ≥6 years and ≥20 kg'
         </a>
         above.)
        </p>
        <p>
         In December 2023, the European Medicines Agency's Committee for Medicinal Products has adopted a positive scientific opinion of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         as treatment of first and second stage rhodesiense HAT in adults and children ≥ 6 years old and weighing ≥ 20 kg [
         <a href="#rid6">
          6
         </a>
         ]. New WHO recommendations are expected soon.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          Fexinidazole
         </a>
         is available from the World Health Organization (WHO) upon request. The drug is not registered for use in most nonendemic countries; it may be obtained for compassionate use within local regulatory frameworks. Fexinidazole is approved by the US Food and Drug Administration (FDA) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration and adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          Fexinidazole
         </a>
         tablets should be swallowed whole within 30 minutes of a meal, which is important for drug absorption [
         <a href="#rid32">
          32
         </a>
         ]. The drug should be administered with solid food; administration with liquids only is associated with significantly diminished absorption. The tablets should not be broken or crushed. Detailed recommendations in case of missed doses or vomiting are given in the WHO guidelines [
         <a href="#rid1">
          1
         </a>
         ]. Follow-up clinical evaluation should be performed at 6, 12, 18, and 24 months after completion of therapy or at any time if symptoms recur [
         <a href="#rid1">
          1
         </a>
         ]. Such follow-up is important given the possibility of incomplete adherence to oral administration and limited data on the likelihood of relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         include neuropsychiatric reactions (insomnia, hallucination, agitation, logorrhea, abnormal behavior, anxiety, psychosis), vomiting (38 percent in adults; 68 percent in children), nausea (33 percent), asthenia (20 percent), anorexia (17 percent), headache (16 percent), insomnia (15 percent), tremor (14 percent), dizziness (14 percent), neutropenia, and QTc prolongation [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting data
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gambiense HAT
         </strong>
         – Use of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         for treatment of first-stage gambiense HAT is supported by two prospective, open-label, single-arm studies; one among 189 adults (DNDiFEX005) and another among 69 children ≥6 years old and ≥20 kg (DNDiFEX006) [
         <a href="#rid33">
          33-35
         </a>
         ]. At 18 months follow-up, treatment failure rates were 2.1 and 1.4 percent, mortality rates were 1.6 and 1.4 percent, adverse event rates were 93.1 and 88.4 percent, and serious adverse event rates were 9.0 and 7.2 percent, respectively [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those with second stage gambiense HAT,
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         was similar to nifurtimox-eflornithine combination therapy (NECT) for those with WBC ≤100, but inferior for those with WBC &gt;100. In a trial including more than 390 patients with &gt;20 CSF WBC/microL or trypanosomes in CSF were randomly assigned (2:1) to treatment with fexinidazole or NECT [
         <a href="#rid33">
          33,34,36
         </a>
         ]. At 24 months follow-up, overall treatment success rates were 89.8 versus 97.6 percent (risk ratio [RR] 0.92, 95% CI 0.87-0.96) [
         <a href="#rid34">
          34,36
         </a>
         ]. Among patients with CSF WBC &gt;100 cells/microL, the treatment success rate at 18 months was lower for fexinidazole than for NECT (86.9 versus 98.7 percent, respectively); among patients with CSF WBC ≤100 cells/microL, the treatment success rates were similar (98 and 95.9 percent, respectively) [
         <a href="#rid33">
          33,36
         </a>
         ]. Rates of adverse effects were similar among fexinidazole and NECT recipients (81 versus 79 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional data on
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         for treatment of second-stage HAT include the DNDiFEX005 trial (41 adults with CSF ≤20 WBC/microL; 97.6 percent fexinidazole treatment success rate) and the DNDiFEX006 trial (56 children; 97.3 fexinidazole treatment success rate) [
         <a href="#rid34">
          34
         </a>
         ]. Further investigation of fexinidazole for treatment of gambiense HAT and rhodesiense HAT is ongoing. [
         <a href="#rid1">
          1,32
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further study of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         for treatment of gambiense HAT will provide additional information on outpatient treatment and adherence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rhodesiense HAT
         </strong>
         – In vitro and in vivo studies have demonstrated that
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         has activity against
         <em>
          T. b.
         </em>
         <em>
          rhodesiense
         </em>
         [
         <a href="#rid14">
          14
         </a>
         ]. A study on the efficacy and safety of fexinidazole in patients with rhodesiense HAT was completed in October 2022, although results have not yet been published [
         <a href="#rid15">
          15
         </a>
         ]. European Medicines Agency (EMA) approved fexinidazole for the treatment of rhodesiense HAT in December 2023 [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H234441099">
         <span class="h3">
          Pentamidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         is recommended for individuals &lt;6 years of age or &lt;20 kg in weight in whom CSF demonstrates WBC ≤5 cells/microL and no trypanosomes. Pentamidine clinical use is further discussed above. (See
         <a class="local">
          'Patients &lt;6 years or &lt;20 kg'
         </a>
         above.)
        </p>
        <p>
         Use of
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         for treatment of first-stage gambiense HAT is supported by two randomized trials and nine observational studies including more than 6700 children and adults [
         <a href="#rid34">
          34
         </a>
         ]. In seven studies including more than 5600 adults and adolescents, the relapse rate at 6 to 24 months was 7.3 percent; in one study including more than 300 children ≤15 years of age, the relapse rate was 3.6 percent [
         <a href="#rid20">
          20,37-43
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         may have efficacy against first-stage rhodesiense HAT, based on case reports of travelers and pharmacologic data [
         <a href="#rid7">
          7,11-13
         </a>
         ]. In regions where pentamidine is more accessible than
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         , pentamidine may be used as initial therapy until suramin therapy can be obtained and administered. (See
         <a class="local">
          'First-stage disease'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         is usually given as an intramuscular injection; this is because intravenous (IV) administration is frequently associated with hypotension (up to 75 percent of cases) [
         <a href="#rid1">
          1
         </a>
         ]. Patients should eat or drink a sugar source to prevent hypoglycemia and should remain supine for at least one hour after injection to reduce the likelihood of hypotension, at which time vital signs should be repeated; monitoring should continue for patients with hemodynamic instability. If pentamidine is administered intravenously, it should be infused slowly over 60 to 120 minutes and vital signs monitored during (and after) infusion. In addition, if feasible, pentamidine should be given with electrocardiogram monitoring and serum glucose monitoring.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         is generally well tolerated; minor adverse reactions are common. Immediate adverse effects include nausea, anorexia, dizziness, pruritus, and hypotension. Sterile abscesses or necrosis may develop at the intramuscular injection site. Pentamidine is also associated with hematologic effects (particularly leukopenia and thrombocytopenia) as well as electrolyte abnormalities (including hyperkalemia, hypomagnesemia, and hypocalcemia). Severe adverse effects include ventricular arrhythmias, pancreatitis, hypo- or hyperglycemia, hepato- and nephrotoxicity with azotemia. Persistent diabetes is rare adverse effect. Pentamidine has been associated with Steven-Johnson syndrome. Seizures and hallucinations have also been described.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         is available from the WHO for the treatment of HAT. Pentamidine is often available in non-HAT endemic countries since it is also used for treatment of
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia.
        </p>
        <p class="headingAnchor" id="H1645549992">
         <span class="h3">
          Nifurtimox-eflornithine combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of NECT is recommended in individuals with confirmed severe second-stage disease (eg, in &lt;6 years of age or &lt;20 kg in weight with CSF WBC &gt;5 cells/microL and/or presence of trypanosomes; in &gt;6 years of age and &gt;20 kg in weight with CSF WBC &gt;100cells/microL) or if lumbar puncture is not feasible. Use of NECT (over eflornithine monotherapy) facilitates shorter duration of therapy, requires a shorter hospital stay, and may reduce the likelihood of selection for resistance. NECT clinical use is further discussed above. (See
         <a class="local">
          'Patients &lt;6 years or &lt;20 kg'
         </a>
         above and
         <a class="local">
          'Patients ≥6 years and ≥20 kg'
         </a>
         above.)
        </p>
        <p>
         Use of NECT for treatment of second-stage gambiense HAT is supported by a trial in the Republic of the Congo and the Democratic Republic of the Congo including more than 280 patients randomly assigned to treatment with NECT (
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          nifurtimox
         </a>
         15 mg/kg orally in 3 doses for 10 days and eflornithine 400 mg/kg IV per day in 2 infusions for 7 days) or eflornithine monotherapy (100 mg/kg IV every 6 hours for 14 days) [
         <a href="#rid44">
          44
         </a>
         ]. After an 18-month follow-up, the patients treated with NECT had a higher cure rate (97.7 versus 91.7 percent; difference -6 percent, one-sided 95% CI -1.5), a lower relapse rate (1.4 versus 5.7 percent), and a lower rate of major adverse effects (14 versus 29 percent). Similarly, in another trial including 163 patients with second-stage gambiense HAT in Uganda randomly assigned to treatment with NECT or eflornithine monotherapy, 18-month cure rates were 90.6 and 88.5 percent, respectively [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Eflornithine infusion catheters should be replaced at least every 48 hours to avoid local site reactions.
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          Nifurtimox
         </a>
         tablets may be cut to achieve the correct dose; if needed, they may be crushed and mixed into food or sugar water. The tablets should be administered under careful supervision to ensure they are swallowed, preferably after a meal. If vomiting occurs within 30 minutes after intake, the same dose should be repeated. If vomiting occurs 30 to 60 minutes after intake, a half dose should be administered.
        </p>
        <p>
         Adverse effects associated with NECT include abdominal pain, nausea, vomiting, headache, seizure, psychotic reaction, and hallucination [
         <a href="#rid46">
          46
         </a>
         ]. Diarrhea and vomiting are frequent (&gt;50 percent of cases) but do not warrant cessation of treatment. Other described adverse effects include tremor, headache, bone marrow suppression (anemia, leukopenia), and vertigo. NECT is better tolerated in children than in adults. Adverse effects of NECT are better tolerated than those associated with eflornithine monotherapy.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          Nifurtimox
         </a>
         is registered for the treatment of Chagas disease in certain countries; for HAT, it is used as compassionate treatment or off-label use, under approbation by pharmaceutical authorities. Eflornithine is available from the WHO and can be also obtained from strategic drug stocks in nonendemic countries  (
         <a class="graphic graphic_table graphicRef130333" href="/z/d/graphic/130333.html" rel="external">
          table 4
         </a>
         ). Eflornithine is approved by the FDA for the treatment of gambiense HAT [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H105324833">
         <span class="h3">
          Eflornithine monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eflornithine monotherapy is an alternative regimen for treatment of second stage gambiense HAT when NECT is not feasible (because
         <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">
          nifurtimox
         </a>
         is unavailable or contraindicated, such as in patients with epilepsy or psychosis) and when
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         cannot be given. Eflornithine is not effective against rhodesiense HAT because this species has a higher turnover rate of the target enzyme.
        </p>
        <p>
         Use of eflornithine monotherapy is supported by a retrospective study including more than 900 patients with second-stage HAT in southern Sudan treated with eflornithine or
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         ; those treated with eflornithine had a lower mortality rate (0.8 versus 3.5 percent; relative risk 0.2, 95% CI, 0.04-0.89) and lower rate of encephalopathy (0.4 versus 11 percent) [
         <a href="#rid48">
          48
         </a>
         ]. In a subsequent cohort study including more than 1000 patients with second-stage HAT in southern Sudan treated with eflornithine monotherapy. Of 924 cases followed, 1.7 percent died during treatment, 7.6 percent relapsed, 1.6 percent died of disease, 43.6 percent were confirmed cured, and 45.5 percent were probably cured [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Eflornithine infusion catheters should be replaced at least every 48 hours to avoid local site reactions.
        </p>
        <p>
         Eflornithine monotherapy is associated with more frequent adverse effects (grade 3 or 4) than NECT (28.7 versus 14 percent) [
         <a href="#rid44">
          44
         </a>
         ]. The main adverse effects are fever, pruritus, hypertension, nausea, vomiting, diarrhea, abdominal pain, headaches, dizziness, hearing loss, seizure, arthralgia, rash, alopecia, and myelosuppression (anemia, leukopenia, and thrombocytopenia) [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p>
         Eflornithine is available from the WHO and can also be obtained from strategic drug stocks in nonendemic countries  (
         <a class="graphic graphic_table graphicRef130333" href="/z/d/graphic/130333.html" rel="external">
          table 4
         </a>
         ). Eflornithine is approved by the FDA for the treatment of gambiense HAT [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2283606801">
         <span class="h3">
          Suramin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         is restricted to treatment of first-stage rhodesiense HAT; it is not effective for second-stage disease due to poor CSF penetration [
         <a href="#rid51">
          51
         </a>
         ]. Use of suramin for treatment of gambiense HAT is supported by data from the 1950s including cure rates of more than 90 percent; however, observed relapse rates were 25 to 35 percent [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         An immediate hypersensitivity reaction leading to nausea, vomiting, shock, and loss of consciousness can occur following
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         administration; the risk of anaphylaxis is 1:20,000 patients [
         <a href="#rid52">
          52
         </a>
         ]. Other adverse effects include nephrotoxicity, peripheral neuropathy, exfoliative dermatitis, and bone marrow toxicity.
        </p>
        <p>
         In patients with onchocerciasis coinfection, treatment with
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         may cause a severe immunologic reaction; however, in general the prevalence of onchocerciasis overlaps with regions of gambiense HAT, not rhodesiense HAT [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5683.html" rel="external">
          "Onchocerciasis"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          Suramin
         </a>
         is available from WHO and can be also obtained from strategic drug stocks in non-endemic countries  (
         <a class="graphic graphic_table graphicRef130333" href="/z/d/graphic/130333.html" rel="external">
          table 4
         </a>
         ). In the United States, suramin is available from the United States Centers for Disease Control and Prevention (CDC) on a compassionate use basis. The CDC Drug Service telephone number is (404) 639-3670 or (404) 770-7100.
        </p>
        <p class="headingAnchor" id="H2977092740">
         <span class="h3">
          Melarsoprol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         for treatment of gambiense HAT is supported by a randomized trial comparing a 10-day regimen with a longer regimen [
         <a href="#rid53">
          53,54
         </a>
         ]. Among 500 patients in Angola, the parasitologic cure rate 24 hours after treatment was 100 percent in both groups; each group had 14 patients with encephalopathy with 6 deaths [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Data supporting use of
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         for treatment of rhodesiense HAT are described above. (See
         <a class="local">
          'Second-stage disease'
         </a>
         above.)
        </p>
        <p>
         Treatment failures with
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         for gambiense HAT were first observed in the 1990s; their incidence rose to 20 to 59 percent reported failure rates until the mid-2000s in regions of Angola [
         <a href="#rid55">
          55
         </a>
         ], the Democratic Republic of Congo [
         <a href="#rid56">
          56,57
         </a>
         ], Uganda [
         <a href="#rid58">
          58
         </a>
         ], and South Sudan [
         <a href="#rid59">
          59,60
         </a>
         ]. Between 2006 and 2010, the use of melarsoprol sharply diminished, and no further reports appeared.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         should not come into contact with water, which may cause precipitation. Use of sterile, dry glass syringes is preferred if good sterilization procedures are feasible. Care must be taken with plastic syringes, since the plastic may be dissolved by propylene glycol (a solvent); therefore, melarsoprol must be administered promptly after it is drawn up into a plastic syringe. Melarsoprol is best given IV via a butterfly as a slow bolus injection. The injection is very painful and causes a local reaction; therefore, another IV site and line must be used for the next dose. Caution must be taken to avoid IV infiltration [
         <a href="#rid1">
          1,7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         −
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         is an arsenical compound associated with high frequency of severe, life-threatening adverse effects [
         <a href="#rid61">
          61
         </a>
         ]. The most feared adverse reaction is arsenic encephalopathy; this occurs in 5 to 18 percent of patients and is fatal in 10 to 70 percent of cases [
         <a href="#rid7">
          7,16,51
         </a>
         ]. Onset of encephalopathy should prompt melarsoprol discontinuation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The syndrome usually occurs 7 to 14 days after the first injection and is characterized by fever and convulsions, rapid onset of neurologic disorders, progressive coma, or abnormal behavior. Close monitoring might allow detection of early signs, such as fever or headache, prompting the cessation of
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         and management with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of encephalopathy increases with the trypanosomal burden and CSF WBC count and may occur as a result of inflammatory response against trypanosomes in the central nervous system. Therefore,
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         should be coadministered with
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (see
         <a class="local">
          'Second-stage disease'
         </a>
         above). In randomized trials, this approach has been associated with reduced risk of melarsoprol-induced encephalopathy (by two-thirds) and reduced mortality (by 50 percent); no effect on treatment efficacy has been observed [
         <a href="#rid17">
          17,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other adverse effects include malaise, abdominal pain, nausea, vomiting, diarrhea, hepatotoxicity, peripheral neuropathy, paraplegia, cardiac arrhythmias, albuminuria, and skin reactions (pruritus); exfoliative dermatitis occurs in less than 1 percent of cases. The injection is very irritating and thrombophlebitis may occur; extravasation of the drug must be avoided, as it leads to severe local inflammation and skin necrosis [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2778.html" rel="external">
          "Arsenic exposure and chronic poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          Melarsoprol
         </a>
         is available from the WHO and can be also obtained from strategic drug stocks in non-endemic countries  (
         <a class="graphic graphic_table graphicRef130333" href="/z/d/graphic/130333.html" rel="external">
          table 4
         </a>
         ). In the United States, melarsoprol is available from the CDC on a compassionate use protocol. The CDC Drug Service telephone number is (404) 639-3670 or (404) 770-7100.
        </p>
        <p class="headingAnchor" id="H2279758061">
         <span class="h2">
          Investigational agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Further study of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         is ongoing. (See
         <a class="local">
          'Fexinidazole'
         </a>
         above.)
        </p>
        <p>
         Early investigational trials of acoziborole, an oral compound for treatment of all stages of gambiense HAT, showed a high efficacy and no major safety concern. In a prospective, single-arm study of 208 adults treated with a single oral dose of acoziborole (that can be taken in fasting state), the treatment success was 100 percent (41/41) in early and intermediate stages and 95.2 percent (159/167) in stage 2 gambiense HAT [
         <a href="#rid62">
          62
         </a>
         ]. Further clinical trials are ongoing.
        </p>
        <p class="headingAnchor" id="H2626650164">
         <span class="h1">
          DRUG ACCESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antitrypanosomal drugs are donated by the manufacturers and distributed by the World Health Organization (WHO) to endemic countries. In addition, there are also strategic stocks in various non-endemic countries  (
         <a class="graphic graphic_table graphicRef130333" href="/z/d/graphic/130333.html" rel="external">
          table 4
         </a>
         ). Drug distribution via the WHO country offices may help avoid delay due to country-specific regulations for importation.
        </p>
        <p class="headingAnchor" id="H2096366625">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, both gambiense and rhodesiense HAT are considered fatal without treatment [
         <a href="#rid7">
          7
         </a>
         ]. Rare anecdotal cases of asymptomatic
         <em>
          T. b. gambiense
         </em>
         infection or resolution without treatment have been described [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2984263822">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tools for prevention of HAT include (1) vector control and veterinary measures and (2) community surveillance with early treatment of identified cases. There is no vaccine available; the parasite's ability to undergo antigenic switching makes vaccine development challenging. There is limited evidence that natural immunity develops following infection [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         From a public health standpoint, gambiense HAT is responsible for a larger burden of disease than rhodesiense HAT. The regions with the highest prevalence and the largest populations at risk are those with political instability and poor infrastructure. Disease elimination can be achieved only with sustained cooperative efforts including the development and deployment of better tools for diagnosis and treatment.
        </p>
        <p class="headingAnchor" id="H450060609">
         <span class="h2">
          Vector control and veterinary measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vector control is important for reduction of human contact with tsetse flies [
         <a href="#rid7">
          7,65
         </a>
         ]. Such interventions should be used in combination with other approaches for disease control.
        </p>
        <p>
         Tsetse flies are visually attracted to blue cloth and tend to land on black cloth; therefore, these colors have been used to attract them to fly traps  (
         <a class="graphic graphic_picture graphicRef130334" href="/z/d/graphic/130334.html" rel="external">
          picture 1
         </a>
         ) and insecticide-treated screens [
         <a href="#rid66">
          66,67
         </a>
         ]. Thus far, insecticidal resistance has not been reported among tsetse flies. Tsetse fly repellents are under development, mainly for veterinary use [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         There are a number of examples of success with vector control:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Chad, combining vector control with treatment of human cases was effective for reducing transmission [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Guinea, under conditions where medical control of HAT could not be maintained due to the Ebola epidemics, vector control alone was effective in providing some degree of protection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Uganda, a prevention campaign against rhodesiense HAT consisted of a bundled approach including mass cattle insecticide spraying (to reduce the number of tsetse flies) and mass treatment of cattle with trypanocidal drugs [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In many African countries, the Pan African Tsetse and Trypanosomiasis Eradication Campaign has employed area-wide vector control interventions [
         <a href="#rid70">
          70-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3748049083">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance may be used for early detection of gambiense HAT; this is helpful for controlling disease as well as reducing ongoing transmission during a potentially prolonged subclinical phase. Surveillance is not practical for rhodesiense HAT, since asymptomatic human infection is rare; the only prevention tools for rhodesiense HAT are vector control and veterinary measures [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="local">
          'Vector control and veterinary measures'
         </a>
         above.)
        </p>
        <p>
         Surveillance for gambiense HAT requires substantial resources and is especially challenging in rural areas where there is little access to health facilities. The appropriate interval between screenings in endemic areas depends on the disease prevalence and transmission intensity. Typically, screening is performed annually; if no new cases are detected for three years, the screening interval is increased to three years, and if no new cases are detected for five years, screening is discontinued [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Surveillance tools for gambiense HAT include clinical screening for lymphadenopathy and serologic screening (typically using the card agglutination test for
         <em>
          T. b. gambiense
         </em>
         trypanosomes [CATT] or a lateral flow assay) [
         <a href="#rid74">
          74-77
         </a>
         ]. The sensitivity of serology is generally &gt;80 percent, depending on the geographic location and the test used [
         <a href="#rid78">
          78
         </a>
         ]. The specificity depends in part upon whether whole blood or plasma dilutions are used. In addition, cross-reactivity with antibodies against nonpathogenic animal trypanosomes can occur. (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Serologic tests'
         </a>
         .)
        </p>
        <p>
         Individuals with positive serology require further evaluation with lymph node aspiration (if lymphadenopathy is present) and/or blood examination for presence of trypanosomes; in the setting of high clinical suspicion for HAT, lumbar puncture may be pursued [
         <a href="#rid35">
          35
         </a>
         ]  (
         <a class="graphic graphic_algorithm graphicRef130705" href="/z/d/graphic/130705.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef130501" href="/z/d/graphic/130501.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">
          "Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical approach'
         </a>
         .)
        </p>
        <p>
         Individuals with trypanosomes detected in any tissue or body fluid should be treated as described above. (See
         <a class="local">
          'Treatment of gambiense HAT'
         </a>
         above.)
        </p>
        <p>
         For individuals with positive serologic test but negative lymph node aspiration and/or blood examination, the optimal management is uncertain [
         <a href="#rid35">
          35
         </a>
         ]. In such cases, the serologic test may be falsely positive; alternatively, some cases may represent asymptomatic infection with low numbers of circulating parasites or “hidden” trypanosomes in the skin or other tissues. Follow-up should be tailored to individual circumstances; potential tools include use of more specific serologic tests, CATT titration, molecular tests, lumbar puncture, and serial follow-up examinations. The approach to subsequent clinical evaluation and management should be guided by local protocols.
        </p>
        <p class="headingAnchor" id="H2338727817">
         <span class="h2">
          Advice for travelers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Travelers should avoid areas known to harbor tsetse flies. Neutral-colored hats, long-sleeved shirts, and long pants of medium weight should be worn; tsetse flies are attracted to bright colors (especially blue) and dark colors (especially black) and can bite through thin fabric [
         <a href="#rid10">
          10
         </a>
         ]. Insect repellant should be used; it may have limited effect on tsetse flies but reduce the risk of other disease transmitted by bug bites. (See
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         .)
        </p>
        <p>
         There is no role for chemoprophylaxis.
        </p>
        <p class="headingAnchor" id="H2334564">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Two forms of disease
         </strong>
         –
         <strong>
         </strong>
         Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites. There are two forms of the disease: an acute form occurring mainly in East and Southern Africa and caused by
         <em>
          Trypanosoma brucei rhodesiense
         </em>
         (rhodesiense HAT) and a more chronic form occurring mainly in West and Central Africa caused by
         <em>
          Trypanosoma brucei gambiense
         </em>
         (gambiense HAT)  (
         <a class="graphic graphic_table graphicRef85846" href="/z/d/graphic/85846.html" rel="external">
          table 1
         </a>
         ). These two-parasite subspecies have identical morphologic appearances, and both are transmitted by tsetse flies (
         <em>
          Glossina
         </em>
         ). However, the two forms of HAT differ with respect to epidemiology, clinical presentation, and management. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of gambiense HAT
         </strong>
         – Management considerations for gambiense HAT include patient age and weight, clinical manifestations, and cerebrospinal fluid (CSF) findings. The approach is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130497" href="/z/d/graphic/130497.html" rel="external">
          algorithm 1
         </a>
         ); drug dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ): (See
         <a class="local">
          'Treatment of gambiense HAT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients &lt;6 years old or &lt;20 kg body weight warrant routine lumbar puncture. For patients with CSF white blood cell (WBC) ≤5 cells/microL and no trypanosomes, we suggest treatment with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with CSF WBC &gt;5 cells/microL and/or presence of trypanosomes, or if lumbar puncture is not feasible, we suggest treatment with nifurtimox-eflornithine combination therapy (NECT) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients &lt;6 years or &lt;20 kg'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients ≥6 years and ≥20 kg in endemic areas, decisions regarding whether to pursue lumbar puncture should be guided by degree of suspicion for severe second-stage disease  (
         <a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">
          table 2
         </a>
         ). Outside of resource-limited settings, CSF examination is preferred for treatment selection. (See
         <a class="local">
          'Patients ≥6 years and ≥20 kg'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with no suspicion for severe second-stage disease, and for patients with CSF WBC ≤100 cells/microL, we suggest treatment with
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (rather than NECT) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given similar treatment success rates with less toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with CSF WBC &gt;100 cells/microL, or if lumbar puncture is not feasible, we suggest treatment with NECT (rather than
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given greater treatment success rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative and rescue therapies for gambiense HAT are summarized above and in the table  (
         <a class="graphic graphic_table graphicRef130335" href="/z/d/graphic/130335.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Alternative and rescue treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of rhodesiense HAT
         </strong>
         –
         <strong>
         </strong>
         Based on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) positive scientific opinion of
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         as treatment of first and second stage rhodesiense HAT in adults and children ≥6 years old and weighing ≥20 kg, we now use fexinidazole as first-line treatment for both first and second stage rhodesiense HAT. New WHO recommendations are expected soon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who cannot receive
         <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">
          fexinidazole
         </a>
         (&lt;6 years of age, weigh less than 20 kg), management of first stage (hemolymphatic) disease (≤5 WBC/microL and no trypanosomes in the CSF) consists of
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         . Management of second stage (meningoencephalitic) disease (&gt;5 WBC/microL and/or presence of trypanosomes in CSF) consists of
         <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">
          melarsoprol
         </a>
         , coadministered with oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         to reduce the likelihood of developing melarsoprol-induced encephalopathy. (See
         <a class="local">
          'Treatment of rhodesiense HAT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to relapse
         </strong>
         –
         <strong>
         </strong>
         For patients with signs or symptoms suggestive of relapse, blood examination and lumbar puncture should be performed. The approach to treatment of relapse depends on the initial treatment, as summarized above. (See
         <a class="local">
          'Approach to relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         –
         <strong>
         </strong>
         There is no vaccine or chemoprophylaxis available for prevention of HAT; tools include (1) vector control and veterinary measures and (2) surveillance for gambiense HAT with early treatment of identified cases. Travelers should avoid areas known to harbor tsetse flies. Neutral-colored clothing should be worn, and insect repellant should be used. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H769228">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dr. Karin Leder, MBBS, FRACP, PhD, MPH, DTMH, Dr. Peter Weller, MD, MACP, and Dr. August Stich, MD, MSc, DTMH, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1 (Accessed on January 23, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet 2017; 390:2397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003; 362:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindner AK, Priotto G. The unknown risk of vertical transmission in sleeping sickness--a literature review. PLoS Negl Trop Dis 2010; 4:e783.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency. Summary of opinion: Fexinidazole Winthrop. 14 Dec 2023. https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-post-authorisation-summary-positive-opinion-fexinidazole-winthrop-ii-16_en.pdf (Accessed on January 08, 2024).
         </li>
         <li class="breakAll">
          World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO expert committee. https://apps.who.int/iris/handle/10665/95732 (Accessed on January 23, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helleberg BB, Gudmundsson KSS, Kurtzhals JAL, Helleberg M. Second stage human African Trypanosomiasis with Trypanosoma brucei rhodesiense treated with fexinidazole. Lancet Infect Dis 2023; 23:e505.
          </a>
         </li>
         <li class="breakAll">
          Mordt OV, Alves D, Seixas J, et al. OA-504 Towards an arsenic-free oral treatment for human African trypanosomiasis due to Tb rhodesiense: a new tool for disease elimination. BMJ Global Health 2023; 8:A17. https://gh.bmj.com/content/8/Suppl_10/A17.1 (Accessed on January 23, 2024).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. African Trypanosomiasis (African Sleeping Sickness). https://wwwnc.cdc.gov/travel/diseases/african-sleeping-sickness-african-trypansosomiasis (Accessed on July 24, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simarro PP, Cecchi G, Paone M, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010; 9:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul M, Stefaniak J, Smuszkiewicz P, et al. Outcome of acute East African trypanosomiasis in a Polish traveller treated with pentamidine. BMC Infect Dis 2014; 14:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiser M, Bray MA, Cal M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 2011; 55:5602.
          </a>
         </li>
         <li class="breakAll">
          ClinicalTrials.gov. Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense. https://clinicaltrials.gov/ct2/show/NCT03974178 (Accessed on December 09, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuepfer I, Schmid C, Allan M, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl Trop Dis 2012; 6:e1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepin J, Milord F, Guern C, et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989; 1:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadjm B, Van Tulleken C, Macdonald D, Chiodini PL. East African trypanosomiasis in a pregnant traveler. Emerg Infect Dis 2009; 15:1866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumba Ngoyi D, Lejon V, N'Siesi FX, et al. Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis. Trop Med Int Health 2009; 14:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumba Ngoyi D, Lejon V, Pyana P, et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2010; 201:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priotto G, Chappuis F, Bastard M, et al. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis. PLoS Negl Trop Dis 2012; 6:e1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pépin J, Milord F, Khonde AN, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khonde N, Pépin J, Niyonsenga T, et al. Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekwanzala M, Pépin J, Khonde N, et al. In the heart of darkness: sleeping sickness in Zaire. Lancet 1996; 348:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deborggraeve S, Lejon V, Ekangu RA, et al. Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. PLoS Negl Trop Dis 2011; 5:e972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lejon V, Ngoyi DM, Boelaert M, Büscher P. A CATT negative result after treatment for human African trypanosomiasis is no indication for cure. PLoS Negl Trop Dis 2010; 4:e590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilboudo H, Camara O, Ravel S, et al. Trypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA. J Infect Dis 2015; 212:1996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Andrade P, Camara M, Ilboudo H, et al. Diagnosis of trypanosomatid infections: targeting the spliced leader RNA. J Mol Diagn 2014; 16:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngay Lukusa I, Van Reet N, Mumba Ngoyi D, et al. Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study. EBioMedicine 2022; 86:104376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiberti N, Lejon V, Hainard A, et al. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2013; 7:e2088.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Fexinidazole. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=513915 (Accessed on July 05, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 2014; 53:565.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency. Assessment report: Fexinidazole Winthrop. https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/fexinidazole-winthrop-assessment-report_en.pdf (Accessed on July 05, 2023).
         </li>
         <li class="breakAll">
          World Health Organization, Evidence summary: systematic review of oral fexinidazole as first line treatment for gambiense human African trypanosomiasis. https://www.ncbi.nlm.nih.gov/books/NBK545510/ (Accessed on January 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindner AK, Lejon V, Chappuis F, et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis 2020; 20:e38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 2018; 391:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastide S, Priotto G, Echochard R, Etard J. Effectiveness of short vs. long treatment schedules with pentamidine in first-stage HAT: a large field cohort study. Tropical Medicine and International Health 2011; 16:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pohlig G, Bernhard SC, Blum J, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. PLoS Negl Trop Dis 2016; 10:e0004363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doua F, Yapo FB. Human trypanosomiasis in the Ivory Coast: therapy and problems. Acta Trop 1993; 54:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eperon G, Schmid C, Loutan L, Chappuis F. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. Acta Trop 2007; 101:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamonneau V, Solano P, Garcia A, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. Trop Med Int Health 2003; 8:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz JA, Simarro PP, Josenando T. Control of human African trypanosomiasis in the Quiçama focus, Angola. Bull World Health Organ 2002; 80:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tongue Kohagne L, Louis F, Dologuele N. Relapse After Treatment with First Stage Drug in Human African Trypanosomiasis: Contribution of Molecular Biology. International Journal of Infectious Diseases 2008; 12:E383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kansiime F, Adibaku S, Wamboga C, et al. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasit Vectors 2018; 11:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. Clin Infect Dis 2013; 56:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale S. Drug for sleeping sickness approved. JAMA 1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008; 336:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milord F, Pépin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992; 340:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pépin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994; 33:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malvy D, Chappuis F. Sleeping sickness. Clin Microbiol Infect 2011; 17:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid C, Nkunku S, Merolle A, et al. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001; 6:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robays J, Nyamowala G, Sese C, et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 2008; 14:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasker E, Lutumba P, Mumba D, et al. Diagnostic accuracy and feasibility of serological tests on filter paper samples for outbreak detection of T.b. gambiense human African trypanosomiasis. Am J Trop Med Hyg 2010; 83:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore A, Richer M. Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health 2001; 6:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett MP, Vincent IM, Burchmore RJ, et al. Drug resistance in human African trypanosomiasis. Future Microbiol 2011; 6:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 191:1922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betu Kumeso VK, Kalonji WM, Rembry S, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial. Lancet Infect Dis 2023; 23:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamonneau V, Ilboudo H, Kaboré J, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 2012; 6:e1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilboudo H, Bras-Gonçalves R, Camara M, et al. Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFα are associated with subsequent disease development. PLoS Pathog 2014; 10:e1004469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagabadouno M, Camara O, Ilboudo H, et al. Ebola outbreak brings to light an unforeseen impact of tsetse control on sleeping sickness transmission in Guinea. BioRxiv 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahamat MH, Peka M, Rayaisse JB, et al. Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). PLoS Negl Trop Dis 2017; 11:e0005792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirados I, Esterhuizen J, Kovacic V, et al. Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. PLoS Negl Trop Dis 2015; 9:e0003822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini RK, Orindi BO, Mbahin N, et al. Protecting cows in small holder farms in East Africa from tsetse flies by mimicking the odor profile of a non-host bovid. PLoS Negl Trop Dis 2017; 11:e0005977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magona JW, Walubengo J. Mass-treatment and insecticide-spraying of animal reservoirs for emergency control of Rhodesiense sleeping sickness in Uganda. J Vector Borne Dis 2011; 48:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabayo JP. Aiming to eliminate tsetse from Africa. Trends Parasitol 2002; 18:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hursey BS. The programme against African trypanosomiasis: aims, objectives and achievements. Trends Parasitol 2001; 17:2.
          </a>
         </li>
         <li class="breakAll">
          Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC). Available at: https://au.int/en/pattec (Accessed on January 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011; 5:e1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978; 58:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2014; 2:e359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisser S, Lumbala C, Nguertoum E, et al. Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study. PLoS Negl Trop Dis 2016; 10:e0004608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Checchi F, Chappuis F, Karunakara U, et al. Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis. PLoS Negl Trop Dis 2011; 5:e1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simarro PP, Ruiz JA, Franco JR, Josenando T. Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quiçama (Angola). Trop Med Int Health 1999; 4:858.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5688 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1 (Accessed on January 23, 2023).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14966556" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Human African trypanosomiasis of the CNS: current issues and challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28673422" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602444" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The trypanosomiases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200416" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The unknown risk of vertical transmission in sleeping sickness--a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200416" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The unknown risk of vertical transmission in sleeping sickness--a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200416" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The unknown risk of vertical transmission in sleeping sickness--a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37890908" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Second stage human African Trypanosomiasis with Trypanosoma brucei rhodesiense treated with fexinidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37890908" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Second stage human African Trypanosomiasis with Trypanosoma brucei rhodesiense treated with fexinidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37890908" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Second stage human African Trypanosomiasis with Trypanosoma brucei rhodesiense treated with fexinidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040555" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22069503" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sleeping sickness in travelers - do they really sleep?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24571399" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Outcome of acute East African trypanosomiasis in a Polish traveller treated with pentamidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21911566" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21911566" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22970329" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2566790" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19891893" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : East African trypanosomiasis in a pregnant traveler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228348" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20047500" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22701752" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7747321" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594669" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8937285" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : In the heart of darkness: sleeping sickness in Zaire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21364966" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20126270" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A CATT negative result after treatment for human African trypanosomiasis is no indication for cure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26080371" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Trypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24814957" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diagnosis of trypanosomatid infections: targeting the spliced leader RNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36436279" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23469311" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23469311" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535888" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535888" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535888" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31879061" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29113731" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effectiveness of short vs. long treatment schedules with pentamidine in first-stage HAT: a large field cohort study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26882015" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7902655" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Human trypanosomiasis in the Ivory Coast: therapy and problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17207760" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12828540" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12378293" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Control of human African trypanosomiasis in the Quiçama focus, Angola.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Relapse After Treatment with First Stage Drug in Human African Trypanosomiasis: Contribution of Molecular Biology
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19559476" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29471865" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23074318" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Drug for sleeping sickness approved
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16080099" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321960" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1355219" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8122565" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The treatment of human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21722252" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10791526" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337407" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11348527" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The situation of sleeping sickness in Angola: a calamity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18507916" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20682885" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diagnostic accuracy and feasibility of serological tests on filter paper samples for outbreak detection of T.b. gambiense human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10674099" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11348529" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Re-emergence of epidemic sleeping sickness in southern Sudan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21958143" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Drug resistance in human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871127" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36460027" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22720107" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25375156" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFαare associated with subsequent disease development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Ebola outbreak brings to light an unforeseen impact of tsetse control on sleeping sickness transmission in Guinea
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28750007" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26267814" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29040267" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Protecting cows in small holder farms in East Africa from tsetse flies by mimicking the odor profile of a non-host bovid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715734" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mass-treatment and insecticide-spraying of animal reservoirs for emergency control of Rhodesiense sleeping sickness in Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12473355" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Aiming to eliminate tsetse from Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11137731" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The programme against African trypanosomiasis: aims, objectives and achievements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11137731" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The programme against African trypanosomiasis: aims, objectives and achievements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21364972" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/747425" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25103304" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27058033" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750745" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10632994" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quiçama (Angola).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
